Patients undergoing surgery for renal cell carcinoma Cancer
Conditions
Interventions
Patients will undergo surgery as standard. We will use tissue from surgery, combined with a blood sample, and take these to the lab.
The tissue will be split into multiple samples, an
Sponsors
Ourotech Limited (trading as Pear Bio)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years old and over 2. Patients with operable kidney cancer 3. Able to give informed consent 4. Able to give 40 ml of blood and surgical sample yields >= 0.4 g of cancerous tissue
Exclusion criteria
Exclusion criteria: 1. Inoperable or metastatic kidney cancer 2. Pre-operative haemoglobin levels below 120g/l 3. Patients who have already commenced chemotherapy, targeted therapy, immunotherapy or radiotherapy 4. Recurrence of cancer from any other site than the kidney 5. Any other disease or finding that renders the patient at high risk of treatment complications or interferes with obtaining informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of the functional dose of FDA-approved drugs for renal cell carcinoma and confirmation of mechanism of action, both intra- and inter-patient variation, measured using cell alive/dead ratio in an ex-vivo assay at days 0 - 5 time points | — |
Secondary
| Measure | Time frame |
|---|---|
| Assess the correlation of biomarkers to ex vivo tumour response via multi-omics analyses. Biomarkers include gene and protein expression (using RNASeq and ELISA) measured against ex-vivo response, which includes measures of cell alive/dead ratios, invasion and migration, and immune cell infiltration at days 0 - 5 timepoints: 1. The relationship between biomarkers and ex vivo response 2. Ordinal regression correlating biomarker response against ex vivo treatment sensitivity/ resistance | — |
Countries
England, United Kingdom
Outcome results
None listed